Jubilant Radiopharma
Jubilant Radiopharma (Jubilant DraxImage Inc.) develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals and dispensing hardware for hospitals, imaging centers, and nuclear medicine departments across the USA, Canada, and Colombia.
- Company typePrivate
- Founded2019
- HeadquartersKirkland, Canada
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Jubilant Radiopharma does
Jubilant Radiopharma, the operating brand of Jubilant DraxImage Inc., is a Canada-incorporated (Kirkland, Québec) radiopharmaceutical business that develops, manufactures, and commercializes diagnostic and therapeutic nuclear medicine products for healthcare providers in the United States, Canada, and Colombia. It operates as a wholly-owned subsidiary of Jubilant Pharma, a diversified pharmaceutical conglomerate, and functions alongside a U.S. operating entity (Jubilant Pharma Holdings Inc., Yardley, PA) and a radiopharmacy services arm (Jubilant DraxImage Radiopharmacies, Inc.). The company's product portfolio centers on FDA- and Health Canada-approved radiopharmaceutical kits and generators—RUBY-FILL® (Rubidium Rb 82 Generator for cardiac PET), the DRAXIMAGE® line (DTPA, MAA, MDP-25, Sestamibi, MDP, Gluceptate, I-131 diagnostic and therapeutic capsules/solutions), HICON® Sodium Iodide I 131 Solution USP for thyroid disease, Drax Exametazime® for leukocyte imaging, Mertiatide and Sulfur Colloid—plus the SMART-FILL® automated radiopharmaceutical dispensing system as a hardware adjunct. Underlying technology is rooted in radiochemistry, lyophilized kit formulation, isotope generator engineering, and specialized manufacturing infrastructure required for handling radioactive materials.
The business model is B2B, selling radiopharmaceutical products and hardware directly to hospitals, imaging centers, and nuclear medicine departments via direct sales, an inside-sales account/RAM (Radiopharmaceutical Material) request system, and a network of radiopharmacy partners for localized preparation and last-mile delivery. Pricing is quote-based and not publicly disclosed, with multi-year contracts typical given the specialized nature, regulatory compliance burden, and radioactive material handling requirements. Customer segments are horizontal across nuclear medicine, cardiology, oncology, radiology, and endocrinology, with primary use cases in cardiac PET (RUBY-FILL), myocardial perfusion imaging (Sestamibi), pulmonary embolism V/Q scans (DTPA, MAA), bone scintigraphy (MDP-25), and thyroid disease diagnosis and therapy (HICON, I-131 capsules/solutions). The company also supports medical affairs activities including clinical trials (e.g., OPTIMUM), investigator-initiated research, continuing medical education grants, and patient/physician educational content.
Jubilant Radiopharma firmographics
Firmographics- Name
- Jubilant Radiopharma
- Legal name
- Jubilant DraxImage Inc.
- Website
- https://draximage.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Jubilant Radiopharma (Jubilant DraxImage Inc.) develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceuticals and dispensing hardware for hospitals, imaging centers, and nuclear medicine departments across the USA, Canada, and Colombia.
- Ownership category
- akta.pro rank
Jubilant Radiopharma industry classification
Industry- Product category
- Nuclear Medicine Pharmaceuticals
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112), Irradiation Apparatus Manufacturing (334517)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)
- akta.pro secondary industries
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG), Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)
Keywords
Where Jubilant Radiopharma is headquartered
LocationHeadquarters
- HQ city
- Kirkland
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Jubilant Radiopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Radiopharmaceutical Products: Sale of diagnostic and therapeutic radiopharmaceutical products for nuclear medicine imaging and treatment applications. Products include generators, isotopes, and radiopharmaceutical formulations sold to healthcare facilities.
- Medical Device/Hardware Sales: Sale of specialized equipment including radiopharmaceutical generators and dispensing systems such as RUBY-FILL® and SMART-FILL® systems
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B quotation-based pricing for healthcare facilities |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Jubilant Radiopharma product offering
Product offeringCore offering
Jubilant Radiopharma develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceutical products for nuclear medicine applications. Its portfolio spans cardiac PET imaging (RUBY-FILL®), myocardial perfusion (DRAXIMAGE® Sestamibi), bone imaging (DRAXIMAGE® MDP/MDP-25), lung perfusion (DRAXIMAGE® MAA), renal and brain imaging (DRAXIMAGE® DTPA), thyroid imaging and therapy (HICON® I-131), and leukocyte labeling (Drax Exametazime®), alongside the SMART-FILL® dispensing system medical device. Products are sold directly to hospitals, imaging centers, and nuclear medicine departments across the USA, Canada, and Colombia.
Product overview
Jubilant Radiopharma (dba Jubilant DraxImage Inc.) is a radiopharmaceutical company that develops, manufactures, and commercializes diagnostic and therapeutic nuclear medicine products. The portfolio includes diagnostic imaging agents (RUBY-FILL® Rubidium Rb 82 Generator for cardiac PET, DRAXIMAGE® Sestamibi for myocardial perfusion, DRAXIMAGE® MDP-25 for bone imaging, DRAXIMAGE® MAA for lung perfusion, DRAXIMAGE® DTPA for renal/brain imaging), therapeutic products (HICON® Sodium Iodide I 131 Solution for thyroid treatment), medical devices (SMART-FILL® Dispensing System), and supporting products like Drax Exametazime® and Sulfur Colloid. The company operates in USA, Canada, and Colombia markets serving heart disease, thyroid disease, lung disease, and bone disease applications.
Differentiator
Problem solved
Functional benefit
Brands
- DRAXIMAGE: Radiopharmaceutical product brand including imaging agents and diagnostic products
- RUBY-FILL
- HICON
- SMART-FILL
- Drax Exametazime
Products and services
- RUBY-FILL® (Rubidium Rb 82 Generator) and Elution System A rubidium-82 generator and elution system used for PET myocardial perfusion imaging to assess heart disease and coronary artery conditions; sold to hospitals and imaging centers.
- DRAXIMAGE® DTPA A radiopharmaceutical chelate used for brain imaging, renal function assessment, and lung ventilation studies.
- DRAXIMAGE® MAA Macroaggregated albumin used for pulmonary perfusion imaging to detect pulmonary embolism and assess lung function.
- DRAXIMAGE® MDP-25 A bone imaging agent used for skeletal scintigraphy to detect bone metastases, fractures, and bone disease.
- DRAXIMAGE® Sestamibi A myocardial perfusion imaging agent used for detecting coronary artery disease and evaluating heart function.
- Drax Exametazime® A radiopharmaceutical used for labeling leukocytes in white blood cell imaging to detect infection and inflammation sites.
- Jubilant Radiopharma™ Mertiatide A renal function imaging agent used for diagnostic procedures to assess kidney structure and function.
- Jubilant Radiopharma™ Sulfur Colloid A radiopharmaceutical colloid used for liver imaging, bone marrow imaging, and gastrointestinal studies.
- HICON® Sodium Iodide I 131 Solution USP A therapeutic radiopharmaceutical solution containing iodine-131 used for treatment of hyperthyroidism and thyroid cancer.
- DRAXIMAGE® I-131 Diagnostic Capsules Capsule formulation of iodine-131 used for thyroid imaging and uptake studies.
- SMART-FILL® Dispensing System A specialized dispensing system for accurate measurement and delivery of radiopharmaceutical doses in clinical settings.
- DRAXIMAGE® MDP (Canada / Colombia market) A bone imaging agent used for skeletal scintigraphy to detect bone metastases and bone disorders, marketed in Canada and Colombia.
- DRAXIMAGE® Gluceptate A radiopharmaceutical used for brain imaging and soft tissue imaging studies (Canada market).
- DRAXIMAGE® I-131 Therapeutic Capsule Capsule formulation of iodine-131 used for therapeutic treatment of thyroid conditions (Canada market).
- DRAXIMAGE® I-131 Diagnostic Solution Liquid formulation of iodine-131 for thyroid diagnostic imaging (Canada market).
- DRAXIMAGE® I-131 Therapeutic Solution Liquid formulation of iodine-131 for therapeutic treatment of thyroid diseases (Canada market).
Companies that use Jubilant Radiopharma
Customer profileSegments3 records
Ideal customer profiles2 records
Jubilant Radiopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Jubilant Radiopharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Evergreen Theragnostics Inc.coreIn June 2023, Jubilant DraxImage Inc. entered into a distribution agreement with Evergreen Theragnostics Inc. for the preparation, sale, and distribution of OCTEVY™ (Ga-68 DOTATOC Injection) doses to PET customers across the United States. This partnership expanded the company's product offerings in PET imaging diagnostics.
- Radiopharmacy PartnerscoreJubilant Radiopharma operates a network of radiopharmacy partners to extend distribution reach and provide localized preparation and delivery of radiopharmaceutical products to healthcare facilities.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Jubilant Radiopharma competitors and assessment
Company assessmentDirect peers
- Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with a portfolio spanning cardiac PET (PYLARIFY®), oncology, and diagnostics. Directly comparable to Jubilant Radiopharma in nuclear medicine product breadth and B2B sales to hospitals/imaging centers.
- Curium Pharma: Curium is one of the world's largest radiopharmaceutical manufacturers, with a diagnostic and therapeutic nuclear medicine portfolio across SPECT, PET, and therapeutic isotopes. Closely comparable in manufacturing scale, product mix, and target customer base.
- Bracco Imaging: Bracco Imaging is a global diagnostic imaging company offering contrast agents and radiopharmaceuticals for nuclear medicine and radiology. Comparable product mix and hospital/imaging-center customer base.
- Cardinal Health: Cardinal Health operates a large radiopharmacy distribution network (Nuclear Pharmacy Services) and supplies radiopharmaceuticals to hospitals across the US. Directly comparable as a radiopharmacy distributor serving the same hospital customer base.
Broad incumbents
- GE HealthCare: GE HealthCare operates a major radiopharmaceutical and PET radiopharmacy business (including PETNET Solutions) alongside broader imaging equipment. Overlaps with Jubilant in diagnostic radiopharmaceuticals but as part of a much larger portfolio.
- Novartis: Novartis leads radioligand therapy via Pluvicto and Lutathera and operates a broad pharmaceutical portfolio. Overlaps with Jubilant in the radiopharmaceutical category but at far greater scale and with a focus on therapeutics.
- Bayer: Bayer's radiology business includes radiopharmaceutical products and is cited as a key market player. Comparable in radiopharmaceutical product category but operates as part of a global pharmaceutical conglomerate.
- Eli Lilly (POINT Biopharma): Eli Lilly acquired POINT Biopharma and is developing a radioligand therapy pipeline in oncology. Comparable as a competitor in the radiopharmaceutical theranostics market cited alongside Jubilant in industry market projections.
- Siemens Healthineers: Siemens Healthineers offers radiopharmacy services and imaging solutions (PET/SPECT equipment and tracer supply) globally. Comparable in serving nuclear medicine departments and operating radiopharmacy supply chains.
Emerging players
- Telix Pharmaceuticals: Telix is a commercial-stage radiopharma company focused on diagnostic and therapeutic agents (e.g., Illuccix® for PSMA-PET). Comparable in product category and B2B hospital sales motion, with overlapping focus on PET imaging agents.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Jubilant Radiopharma social profiles
Digital presenceJubilant Radiopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jubilant Radiopharma leadership team
Management profileNumber of profiles
Jubilant Radiopharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Jubilant Radiopharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jubilant Radiopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jubilant Radiopharma
What does Jubilant Radiopharma do?
Jubilant Radiopharma develops, manufactures, and commercializes diagnostic and therapeutic radiopharmaceutical products for nuclear medicine applications. Its portfolio spans cardiac PET imaging (RUBY-FILL®), myocardial perfusion (DRAXIMAGE® Sestamibi), bone imaging (DRAXIMAGE® MDP/MDP-25), lung perfusion (DRAXIMAGE® MAA), renal and brain imaging (DRAXIMAGE® DTPA), thyroid imaging and therapy (HICON® I-131), and leukocyte labeling (Drax Exametazime®), alongside the SMART-FILL® dispensing system medical device. Products are sold directly to hospitals, imaging centers, and nuclear medicine departments across the USA, Canada, and Colombia.
Is Jubilant Radiopharma a public or private company?
Jubilant Radiopharma is a private company. It is classified as corporate owned and is currently operating.
When was Jubilant Radiopharma founded?
Jubilant Radiopharma was founded in 2019. It employs 101 to 250 people.
Where is Jubilant Radiopharma based?
Jubilant Radiopharma is headquartered in Kirkland, Canada, in the North America region.
How does Jubilant Radiopharma make money?
Two revenue lines are on record. Radiopharmaceutical Products are the primary driver. The others are medical Device/Hardware Sales.
Who are Jubilant Radiopharma's main competitors?
Direct peers on record are Lantheus Holdings, Curium Pharma, Bracco Imaging and Cardinal Health. Broad incumbents are GE HealthCare, Novartis, Bayer, Eli Lilly (POINT Biopharma) and Siemens Healthineers. Telix Pharmaceuticals is listed as an emerging player.
Does Jubilant Radiopharma have an API?
No public API is recorded for Jubilant Radiopharma.
What industry is Jubilant Radiopharma in?
Jubilant Radiopharma's product category is Nuclear Medicine Pharmaceuticals. Its primary akta.pro industry code is HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 3391 and its SIC code is 2835.